66521-84-4

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydrobenzo[h]quinazolin-2-amine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of potential drug candidates with therapeutic applications.
Used in Chemical Research:
5,6-Dihydrobenzo[h]quinazolin-2-amine is used as a research compound in the field of organic chemistry. It serves as a model compound for studying the properties and reactivity of benzimidazoles and quinazolines, contributing to the understanding of their chemical behavior and potential applications.
Used in Material Science:
5,6-Dihydrobenzo[h]quinazolin-2-amine may be used as a component in the development of new materials with specific properties, such as in the synthesis of novel polymers or as a part of a molecular structure in supramolecular chemistry.
Used in Agrochemical Industry:
5,6-Dihydrobenzo[h]quinazolin-2-amine could be used as a starting material for the synthesis of agrochemicals, such as pesticides or herbicides, due to its potential bioactivity and chemical properties.

InChI:InChI=1/C12H11N3/c13-12-14-7-9-6-5-8-3-1-2-4-10(8)11(9)15-12/h1-4,7H,5-6H2,(H2,13,14,15)

Upstream product

• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 50-01-1 guanidine hydrochloride 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 34773-02-9 2-(Dimethylaminomethylene)-3,4-dihydro-1(2H)-naphthalenone 

Downstream Products

• 4786-77-0 5,6-dihydrobenzo[h]quinazolin-2(3H)-one 

Relevant academic research and scientific papers

SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

New polycyclic pyrimidine derivatives with antiplatelet in vitro activity: Synthesis and pharmacological screening

The preparation and the pharmacological screening of novel anti-aggregatory/antiphlogistic polycyclic pyrimidine derivatives are described. The compounds were developed starting from bioactive 2-aminobenzopyranopyrimidine derivatives in order to assess the importance of the benzopyrano[4,3-d]pyrimidine structure and the role of an amino basic moiety in position 2. Antiplatelet activity was assessed in vitro against ADP and arachidonic acid-induced aggregation in guinea-pig plasma. Anti-inflammatory/analgesic/antipyretic activities were studied in rat paw oedema, mouse writhing test and E coli-induced rat fever. Ulcerogenic and gastroprotective effects were also investigated in vivo on rat gastric mucosa. Among the tested compounds, the 5-substituted benzopyranopyrimidine derivatives 3d and 4d proved to be the most active antiplatelet agents as potent as acetylsalicylic acid against arachidonic acid-stimulated aggregation. Furthermore the 2-methylthio derivative 4d was endowed with greater efficacy against ADP aggregation suggesting that additional non-TXA2 dependent mechanisms are involved in its biological activity. Orally administered at 100mgkg-1 in rats this latter compound displayed antiphlogistic acitivity comparable to indomethacin (10 mg kg -1) coupled with an unusual gastroprotective effect on ethanol-induced ulcers. In conclusion, these findings indicate that the 5-pyrrolidino-2-methylthiobenzopyrano[4,3-d]pyrimidine 4d fulfils the chemical requirements to exhibit antiplatelet activity associated with gastroprotective effect. Copyright